Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Acute Coronary Syndrome (ACS)
4.9
$ 11.50
In stock
(637)
Product Description
Antiplatelet therapy after percutaneous coronary intervention - EuroIntervention
ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More
Acute Myocardial Infarction: A Shifting Paradigm
APSC Recommendations on the Use of P2Y12 Inhibitors in Asia
Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Acute Coronary Syndrome (ACS)
GLOBAL LEADERS design. ACS, acute coronary syndrome; ASA, aspirin; CAD
Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis
Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark - The Lancet Regional Health – Europe
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review - ScienceDirect
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk
Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy - ScienceDirect
/cloudfront-us-east-1.images.arcpublishing.com/gray/2WDOMSHGLZIB7N7QIFZTBVB6EQ.jpg "How to Stream the Steelers vs. 49ers Game Live - Week 1")
